Quote:

---

We are continuing to evaluate shareholder value creating arrangements for our diagnostics division, including a potential ‘spin-out’ or other business arrangements that would make strategic sense for the various LymPro and Amarantus stakeholders . We will not be giving additional details related to those possible arrangements in today’s business update call, as we are contractually prohibited from doing so.

---

See more at: http://www.thechairmansblog.com/amarantus-bio...IS23T.dpuf

It reads a little different to me now. I didn't pick up on the differentiation before.


Cheers